What does Pharma Legrand do?

Pharma Legrand is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 27 July 2021, 1 establishment.

What is the address of Pharma Legrand?

The registered office of Pharma Legrand is located at Molenstraat 1 box A, 8980 Zonnebeke.

Is Pharma Legrand still active?

Yes. According to the CBE (31 October 2026) Pharma Legrand is active, legal situation “Normale toestand”, started on 27 July 2021.

Is Pharma Legrand registered on Peppol?

Yes, Pharma Legrand is registered on the Peppol network with ID 0208:0771765553.

What is the enterprise number of Pharma Legrand?

The enterprise number of Pharma Legrand is BE0771765553.

When was Pharma Legrand founded?

Pharma Legrand was founded on 27 July 2021.

Who are the directors of Pharma Legrand?

According to the 2025 annual accounts, the directors of Pharma Legrand are: Lore Legrand.

Is Pharma Legrand a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 July 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Pharma Legrand make in 2025?

Pharma Legrand posted a profit after taxes of € 162,257 in financial year 2025.

What is the revenue of Pharma Legrand?

As a small company, Pharma Legrand is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 303,401.

Pharma Legrand (Private Limited) - Zonnebeke

Dossier Pharma Legrand, printed on 31 October 2026 from databakkes.be/en/0771765553/pharma-legrand. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 10 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Pharma Legrand from Zonnebeke, company number BE0771765553, closed financial year 2025 with a result of € 162,257 after tax. For that financial year Pharma Legrand recorded a gross margin of € 303,401 and equity of € 272,538. Compared with financial year 2024, the result moved from € 98,386 to € 162,257. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.

What it is worth Healthy

€ 272,538

▼ 37% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 162,257

▲ 65% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 53,602

▲ 103% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 320,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

Debts at end 2025

Bank debt ≈ 14 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.7 million

▼ 7% vs 2024

€ 116,667 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.

Owed to suppliers

€ 12,111

▲ € 11,466 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 29,525

▼ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 124,877 Gross margin 2022: € 124,877 First fiscal year in the series	€ 322,751 Gross margin 2023: € 322,751 ▲ 158% vs 2022 (€ 124,877) Favourable step	€ 219,606 Gross margin 2024: € 219,606 ▼ 32% vs 2023 (€ 322,751) Unfavourable step	€ 303,401 Gross margin 2025: € 303,401 ▲ 38% vs 2024 (€ 219,606) Favourable step	▲ 38%
Profit after taxes	€ 95,711 Profit after taxes 2022: € 95,711 First fiscal year in the series	€ 233,980 Profit after taxes 2023: € 233,980 ▲ 144% vs 2022 (€ 95,711) Favourable step	€ 98,386 Profit after taxes 2024: € 98,386 ▼ 58% vs 2023 (€ 233,980) Unfavourable step	€ 162,257 Profit after taxes 2025: € 162,257 ▲ 65% vs 2024 (€ 98,386) Favourable step	▲ 65%
Equity	€ 99,911 Equity 2022: € 99,911 First fiscal year in the series	€ 332,909 Equity 2023: € 332,909 ▲ 233% vs 2022 (€ 99,911) Favourable step	€ 430,281 Equity 2024: € 430,281 ▲ 29% vs 2023 (€ 332,909) Favourable step	€ 272,538 Equity 2025: € 272,538 ▼ 37% vs 2024 (€ 430,281) Unfavourable step	▼ 37%
Total debts	€ 2,232,247 Total debts 2022: € 2,232,247 First fiscal year in the series	€ 2,089,381 Total debts 2023: € 2,089,381 ▼ 6% vs 2022 (€ 2,232,247) Favourable step	€ 1,953,226 Total debts 2024: € 1,953,226 ▼ 7% vs 2023 (€ 2,089,381) Favourable step	€ 2,071,995 Total debts 2025: € 2,071,995 ▲ 6% vs 2024 (€ 1,953,226) Unfavourable step	▲ 6%
Cash	€ 4,066 Cash 2022: € 4,066 First fiscal year in the series	€ 132,148 Cash 2023: € 132,148 ▲ € 128,083 vs 2022 (€ 4,066) Favourable step	€ 26,459 Cash 2024: € 26,459 ▼ 80% vs 2023 (€ 132,148) Unfavourable step	€ 53,602 Cash 2025: € 53,602 ▲ 103% vs 2024 (€ 26,459) Favourable step	▲ 103%
Retained profit	€ 94,911 Retained profit 2022: € 94,911 First fiscal year in the series	€ 327,909 Retained profit 2023: € 327,909 ▲ 245% vs 2022 (€ 94,911) Favourable step	€ 425,281 Retained profit 2024: € 425,281 ▲ 30% vs 2023 (€ 327,909) Favourable step	€ 267,538 Retained profit 2025: € 267,538 ▼ 37% vs 2024 (€ 425,281) Unfavourable step	▼ 37%
Dividend	€ 800 Dividend 2022: € 800 First fiscal year in the series	€ 983 Dividend 2023: € 983 ▲ 23% vs 2022 (€ 800) Unchanged	€ 1,014 Dividend 2024: € 1,014 ▲ 3% vs 2023 (€ 983) Unchanged	€ 320,000 Dividend 2025: € 320,000 ▲ € 318,986 vs 2024 (€ 1,014) Unchanged	▲ € 318,986
Bank debt	€ 2,200,000 Bank debt 2022: € 2,200,000 First fiscal year in the series	€ 1,883,333 Bank debt 2023: € 1,883,333 ▼ 14% vs 2022 (€ 2,200,000) Favourable step	€ 1,766,667 Bank debt 2024: € 1,766,667 ▼ 6% vs 2023 (€ 1,883,333) Favourable step	€ 1,650,000 Bank debt 2025: € 1,650,000 ▼ 7% vs 2024 (€ 1,766,667) Favourable step	▼ 7%
Balance sheet total	€ 2,332,158 Balance sheet total 2022: € 2,332,158 First fiscal year in the series	€ 2,422,289 Balance sheet total 2023: € 2,422,289 ▲ 4% vs 2022 (€ 2,332,158) Unchanged	€ 2,383,507 Balance sheet total 2024: € 2,383,507 ▼ 2% vs 2023 (€ 2,422,289) Unchanged	€ 2,344,533 Balance sheet total 2025: € 2,344,533 ▼ 2% vs 2024 (€ 2,383,507) Unchanged	▼ 2%

Key figures of Pharma Legrand, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Pharma Legrand?

What happened at Pharma Legrand in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2026 New annual accounts for financial year 2025: profit of € 162,257 (▲ 65% vs 2024). Source: NBB ↗
Jul 27, 2021 New establishment in Zonnebeke. KBO
Jul 27, 2021 Start of the company according to the CBE. KBO

In short

From € 95,711 profit in 2022 to € 162,257 profit in 2025.

Paid € 150,431 in corporate taxes since 2022.

Best year ever: 2023, with € 233,980 profit.

Paid out € 322,797 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Lore Legrand

Pharma Legrand

Apotheek Legrand 100%

Behind Pharma Legrand is Lore Legrand. It owns 100% of Apotheek Legrand itself.

Directors

According to the 2025 annual accounts

Lore Legrand

Director

Also active at: Apotheek Legrand

Establishments

Establishment units

Physical locations of this company

Registered office

Molenstraat 1 box A

8980 Zonnebeke

2.320.413.907

Molenstraat 1/A

8980 Zonnebeke

Active since 27 July 2021

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0771.765.553

VAT number

BE 0771.765.553

Registered office

Molenstraat 1 bus A, 8980 Zonnebeke

Names & denominations

Pharma Legrand

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 July 2021

Peppol

Active · Active since 17 Mar 2025

Activities · NACE

Activiteiten van holdings

Holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige zakelijke dienstverlening, neg

Activiteiten van adviesbureaus op het gebied van public relations en communicatie

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Adviesbureaus op het gebied van public relations en communicatie

View on CBE Public ↗ Annual accounts (NBB) ↗

Pharma Legrand

Warning lights

Financials

What happened to Pharma Legrand?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions